Related Experiment Video
Updated: Jan 12, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
890
Review on obesity management: diet, exercise and pharmacotherapy
1Medicine, McGill University, Montreal, Quebec, Canada.
BMJ Public Health
|November 7, 2025
Summary
Obesity is a major risk factor for cardiometabolic disease. This review explores clinical guidelines for managing obesity, including lifestyle changes and medications, as a tiered approach to treatment.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Background:
- Obesity is a significant and growing risk factor for cardiometabolic disease in North American adults.
- The increasing prevalence of obesity necessitates effective clinical management strategies.
Purpose of the Study:
- To review current clinical guidelines for managing overweight and obese patients.
- To explore tiered management strategies, including lifestyle interventions and pharmacotherapy.
Main Methods:
- Review of clinical guidelines from Canada and Europe.
- Analysis of first-line and second-line treatment approaches for obesity management.
Main Results:
- Guidelines recommend a tiered approach to obesity management.
- First-line treatments include diet, exercise, and behavioral therapy.
- Second-line treatments involve the use of antiobesity medications.
Conclusions:
- Current guidelines provide a framework for physicians to manage obesity.
- A combination of lifestyle modifications and pharmacotherapy is essential for effective obesity treatment.
- Continued exploration of management strategies is crucial to mitigate the spread of obesity.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
853
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
853
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
230
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230
Drug Dosing: Obese Patients
208
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
208
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
163
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
163
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K

